CLINICAL TRIALS PROFILE FOR RESMETIROM
✉ Email this page to a colleague
All Clinical Trials for resmetirom
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT03900429 ↗ | A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis | Recruiting | Madrigal Pharmaceuticals, Inc. | Phase 3 | 2019-03-28 | A double-blind placebo controlled randomized Phase 3 study to determine if 80 or 100 mg of MGL-3196 as compared with placebo resolves NASH on liver biopsy and prevents progression to cirrhosis and/or advanced liver disease |
NCT04197479 ↗ | A Phase 3 Study to Evaluate the Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease (NAFLD) Patients | Recruiting | Madrigal Pharmaceuticals, Inc. | Phase 3 | 2019-12-16 | A double-blind placebo controlled randomized Phase 3 study to evaluate the safety and tolerability of once-daily, oral administration of 80 or 100 mg resmetirom versus matching placebo. 100 patients will be enrolled in a 100 mg open-label arm. |
NCT04951219 ↗ | A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) | Recruiting | Madrigal Pharmaceuticals, Inc. | Phase 3 | 2021-07-09 | A 52-Week, Multi-center, Open-label, Active Treatment Extension Study to Evaluate Safety and Tolerability of Once Daily, Oral Administration of Resmetirom (MGL-3196) |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for resmetirom
Condition Name
Clinical Trial Locations for resmetirom
Trials by Country
Clinical Trial Progress for resmetirom
Clinical Trial Phase
Clinical Trial Sponsors for resmetirom
Sponsor Name